TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04242888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic manual therapies
Description: three of the intervention are novel and the rest of the interventions are in practice but seldom used to treat the shoulder disorder.
Study: NCT00909948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and total body irradiation
Description: The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total body irradiation
Description: Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
Study: NCT04200248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: RBM-007 Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: RBM-007 Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: EYLEA® (aflibercept) Injection, for Intravitreal Use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: EYLEA® (aflibercept) Injection, for Intravitreal Use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Sham intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham intravitreal injection
Study: NCT03528746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Exercise
Description: Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
Study: NCT00624962

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: nutritional intervention
Description: Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
Study: NCT00721045

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 25 M allogeneic MPCs by transendocardial injection and mapping.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 75 M allogeneic MPCs by transendocardial injection and mapping.
Study: NCT02885506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of P218 capsules
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral administration of P218 matching placebo
Description: Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
Study: NCT01992146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Target-controlled naloxone-infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02516605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: LJN452
Description: LJN452 capsules administered once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 1: Placebo
Description: Matching placebo capsules administered once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: LJN452 Dose level 1
Description: LJN452 capsules administered once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part 2: Placebo
Description: Matching placebo to LJN452 administered once a day for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: LJN452 Dose level 2
Description: LJN452
Study: NCT04675437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12-weeks aerobic exercise program
Study: NCT03334929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset
Description: The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
Study: NCT01935830

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11c] LAAM
Description: intravenous administration of 15-20 mCi of \[11c\] LAAM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of \[11c\] LAAM.
Study: NCT04374006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: we gave 0,2 ml to each rat everyday to negative control groups, and we gave no treatment to sham groups
Study: NCT01438606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-Indiana HIV gag vaccine
Description: Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection (normal saline)
Description: Administered IM in both deltoids at baseline and Week 8.
Study: NCT01640444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + bevacizumab
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI + cetuximab
Description: * Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~* FOLFIRI:~  * Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~ * Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~ * 5-FU 400 mg/m2 iv bolus, followed by~ * 5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle).
Study: NCT03314272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space Glucose Control
Description: Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
Study: NCT04701736

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picture Medication Calendar
Study: NCT02868957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impression data from reference scanner
Description: To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impression data from reference scanner
Description: To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTero
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTero
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trios
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trios
Description: The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
Study: NCT01962818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFOV combined with sigh breaths
Description: It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh
Study: NCT00108004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pramlintide acetate
Description: Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
Study: NCT03452943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: 6, 9, 12, 15, and 18 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to TEV-50717 tablets will be taken BID for 12 weeks.
Study: NCT00721045

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Precursor Cells (MPCs)
Description: 150 M allogeneic MPCs by transendocardial injection

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard-of-care treatment with mock mapping and injection procedures.
Description: Mock
Study: NCT03162874

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: BID
Study: NCT03865641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Description: Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
Study: NCT01099397

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Description: For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
Study: NCT02656953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VDU lenses (Zeiss® Officelens Plus)
Description: The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive lenses (Zeiss® Multifocal Precision Plus)
Description: The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
Study: NCT00624962

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: therapeutic nutritional supplementation
Description: enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
Study: NCT01582997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
Study: NCT05164900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pterygium excision with sutures fixed conjunctival auto-graft
Description: Pterygium excision with vicryl 8/0 fixed conjunctival auto-graft under local anesthesia. During the follow up period, indicators of ocular irritation were assessed.
Study: NCT00721045

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard-of-care treatment with mock mapping and injection procedures.
Description: Mock

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard-of-care treatment with mock mapping and injection procedures.
Description: Mock
Study: NCT02994329

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick® HIV Self-Test (Orasure Technologies, Thailand)
Description: All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
Study: NCT01469442

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Biliary duct stent in the bile duct by cystic way
Description: The size of the external biliary duct stent depending of cystic duct size
Study: NCT03335722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metronome-timed speech
Description: Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Metronome-timed speech
Description: Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: 1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
Study: NCT01803958

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial breast irradiation
Study: NCT00546949

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal invasive decompression
Description: foraminotomy, laminotomy, microscopic decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interspinous Process Decompression (IPD)
Description: Interspinous device